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Qualitative  trapping  proﬁle  of  reactive  metabolites  arising  from  six  structurally  different  compounds
was  tested  with  three  different  d-peptide  isomers  (Peptide  1, gly–tyr–pro–cys–pro–his-pro;  Peptide  2,
gly–tyr–pro–ala–pro–his–pro;  Peptide  3, gly–tyr–arg–pro–cys–pro–his–lys–pro)  and glutathione  (GSH)
using  mouse  and  human  liver  microsomes  as  the  biocatalyst.  The  test  compounds  were  classiﬁed  either
as clinically  “safe”  (amlodipine,  caffeine,  ibuprofen),  or  clinically  as  “risky”  (clozapine,  nimesulide,  ticlo-
pidine;  i.e.,  associated  with  severe  clinical  toxicity  outcomes).  Our  working  hypothesis  was  as follows:
could  the  use  of  short  different  amino  acid  sequence  containing  d-peptides  in adduct  detection  confer
any  add-on  value  to that obtained  with  GSH?  All  “risky”  agents’  resulted  in the  formation  of  several  GSH
adducts  in the  incubation  mixture  and  with  at least  one  peptide  adduct  with  both  microsomal  prepara-
tions.  Amlodipine  did  not  form  any  adducts  with  any  of  the  trapping  agents.  No  GSH  and  peptide  2 and
3  adducts  were  found  with  caffeine,  but with  peptide  1 one  adduct  with  human  liver microsomes  waseactive metabolites
ovalent binding
eptide d-isomer
eptide adducts
detected.  Ibuprofen  produced  one  Peptide  1-adduct  with  human  and mouse  liver  microsomes  but  not
with  GSH.  In conclusion,  GSH  still  remains  the gold  trapping  standard  for reactive  metabolites.  However,
targeted  d-peptides  could  provide  additional  information  about  protein  binding  potential  of  electrophilic
agents,  but  their  clinical  signiﬁcance  needs  to be clariﬁed  using  a wider  spectrum  of chemicals  together
with  other  safety  estimates.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY. Introduction
The metabolic activation of a drug to an electrophilic reactive
etabolite and its covalent binding to cellular macromolecules,
uch as proteins or nucleic acids, is considered to be one of
any ways that drugs exert their toxicity. The adducts formed
an cause either acute or long-term toxicity, e.g., degenerative
iseases [5,25,54]. A thorough toxicological hazard and risk assess-
ent should include determination of the electrophilic potential
f a drug and potential for adduct formation, which are related
n this type of evaluation. However, it is difﬁcult to monitor the
ormation of electrophilic reactive metabolites because they are
nstable. Furthermore, usually the amounts of these compounds
roduced are very small compared to major metabolites or the par-
nt molecule. Thus, different types of trapping agents are needed
o measure the formation of electrophilic compounds. Glutathione
GSH) is the most commonly used trapping agent [3,37,38] because
∗ Corresponding author. Fax: +35 817162424.
E-mail address: markku.pasanen@uef.ﬁ (M.  Pasanen).
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214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
it forms conjugates with many different kinds of electrophiles.
Other trapping agents are: N-acetylcysteine, [14,52], potassium
cyanide (KCN) [2,5,37,38], semicarbazide [37,59], methoxylamine
[57], -glutamylcysteinyllysine [56] and some other synthetic
peptides [33,21,51]. In addition, ferrocenyl-modiﬁed glutathione
(FP)-GSH has been used instead of GSH because (FP)-GSH has higher
retention times than GSH [17]. Furthermore, a bromine-containing
glutathione analog [23] has been claimed to increase sensitivity
compared to unmodiﬁed GSH.
New liquid chromatography–mass spectrometry (LC/MS) tech-
niques are very powerful analytical tools for elucidating the
metabolism of xenobiotics [43,42,49]. Ion trap instruments with
rapid scanning speeds allow the sensitive detection of metabolites
and the acquisition of their mass spectra in a single LC/MS run. The
triple quadrupole-linear ion trap technique expands the range of
metabolite screening [16,40].
In this study, we evaluated the trapping properties
of three synthetic d-peptides with different sequences
(gly–tyr–pro–cys–pro–his–pro (Peptide 1), gly–tyr–pro–ala–pro–
his–pro (Peptide 2) and gly–tyr–arg–pro–cys–pro–his–lys–pro
(Peptide 3) and compared them to GSH. Potential electrophiles
were produced from three clinically “safe” drugs (amlodipine,
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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CFig. 1. Chemical struct
affeine and ibuprofen) and from three clinically “risky” drugs
clozapine, nimesulide and ticlopidine) (Fig. 1) in in vitro incu-
ations using control mouse and human liver microsomes as
he enzyme source. The identiﬁcation of adducts was  based on
heir fragmentation in LC/MS ion-trap mass-spectrometry with an
lectrospray ionization (ESI) source.
. Materials and methods
.1. Chemicals
Glutathione (GSH), MgCl2, NADPH, potassium phosphate,
mlodipine, caffeine, clozapine, ibuprofen, nimesulide and
iclopidine were purchased from Sigma–Aldrich chemi-
als (Helsinki, Finland). Acetonitrile was from J.T. Baker
St. Louis MO,  USA) and formic acid from Merck KGaA
Darmstadt, Germany). d-Isomer peptides (gly–tyr–pro–cys–
ro–his–pro, gly–tyr–pro–ala–pro–his–pro and gly–tyr–arg–pro–
ys–pro–his–lys–pro) were synthesized by GL Biochem (Shanghai,
hina) and had a purity of >95%.f the test compounds.
2.2. Biological material
Human liver microsomes were purchased from BD Biosciences
(Woburn, MA,  USA). DBA/2N/Kuo mice were obtained from the
National Laboratory Animal Centre, Kuopio University. Liver micro-
somes and the cytosolic fraction were prepared from the livers of
animals as described previously [22]. The animals had unrestricted
access to water and standard chow (Lactamin R36, Lactamin AB,
Södertälje, Sweden). The Ethics Committee for Animal Experi-
ments, University of Kuopio approved these experiments.
2.3. Adduct formation with six test compounds
The incubation conditions were as described below. Because the
enzyme sources used were pooled microsomes of human or mouse
origin, the incubations were carried out twice and as duplicates.
The 500-l incubation mixture contained 100 mM potassium phos-
phate buffer, pH 7.4, 2.5 mM MgCl2, 0.5 mM NADPH, 0.30 mg/ml
of microsomal protein, the substrate concentration was 50 M
(amlodipine, caffeine, clozapine, ibuprofen, nimesulide and ticlo-
pidine), and the trapping substance concentration was  572 M for
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-peptides 1–3 or 1 mM for GSH. Incubation time was  1 h at 37 ◦C.
he incubation mixture was  preheated at 37 ◦C for 10 min, the oxi-
ation reaction was started by adding NADPH and the reaction was
erminated by addition of an equal volume of acetonitrile. Three
inds of controls were used: incubations without NADPH, enzyme
ource or substrate. The selection of 572 M peptide trapping con-
entration was based on the fact that at higher concentrations
eptides would cause problems in the LC/MS analysis because the
eptide could precipitate in the column and ion source. Unlike GSH,
hich comes out at very early times in the LC run, the non-adducted
eptides cannot be diverted to waste at the beginning of LC sepa-
ation due to relatively long retention times. The test tubes were
entrifuged for 20 min  at 2000 × g. Supernatant (500 l) was taken
nd the acetonitrile was evaporated for 1 h at room temperature in
n evaporating centrifuge. The residuals were dissolved in 250 l
f water and centrifuged again for 10 min. Blank samples did not
ontain either substrate or trapping agent. The duplicate samples
ere measured with an LC/MS spectrometer.
.4. LC/MS analysis of the adducts
The peptides or GSH were adducted with the substrates in vitro
n the presence of the enzyme source, and the fragment ions of
dducts were analyzed by LC/MS. Each comparative experiment in
his study was incubated and analyzed as a single batch. LC separa-
ion was carried out using an Agilent 1200 Series Binary Pump SL
ump system and an Agilent 1200 Autosampler (Agilent Technolo-
ies, Inc., Santa Clara, CA, USA) equipped with an Agilent Zorbax
B-C18 Rapid Resolution HT column (150 mm × 2.1 mm,  1.8 m)
nd a Phenomenex Gemini-NX C18 guard column (4 mm × 2.0 mm)
Phenomenex, Torrance, CA, USA). The injection volume was 10 l
nd the ﬂow rate was 100 l/min. Eluent A was 0.1% formic acid in
ater and eluent B was 0.1% formic acid in 90% acetonitrile and 10%
ater. Eluent B was held at 5% for 2 min, then increased from 5%
o 100% in 15 min  and held at 100% B for 1 min. The gradient was
hen decreased from 100% to 5% B in 1 min  and the column was
tabilized by 11 min  ﬂow of 5% eluent B. Autosampler temperature
as 10 ◦C and column temperature was held at 35 ◦C.
A Finnigan LTQ linear ion trap mass spectrometer was  used for
he detection of the formed adducts. The instrument was  equipped
ith an electrospray ionization source and operated in the posi-
ive ion mode. A divert valve was used to direct the eluent ﬂow to
he mass spectrometer from 6 to 22 min  of the LC run. The spray
as stabilized with a nitrogen sheath ﬂow with a value set to 30
nstrument units, the spray needle voltage was 4 kV, the stainless
teel capillary temperature was 230 ◦C and the capillary voltage
as 19 V. The collision energy was 40 V and the isolation width
sed was 2.0 for MS2. Full-scan mass spectra were used to verify the
olecular weights of the analysed adducts. The qualitative identiﬁ-
ation of the GSH and peptide adduct proﬁles formed was  based on
heir typical MS2  fragment ions, which were predicted using Pro-
einProspector software (available at: http://prospector.ucsf.edu/
rospector/cgi-bin/mssearch.cgi). Data acquisition was performed
sing Xcalibur DATA System 2.0 software (Thermo Electron Corpo-
ation, Waltham, MA,  USA).
. Results and discussion
Detection of reactive metabolites is based on their reactivity
nd conjugation with trapping agents. The synthesized d-peptides
sed in the study contained nucleophilic lysine, cysteine, histidine
r arginine, which can react with electrophilic compounds. “Soft”
lectrophiles (quinones, quinone imines, epoxides, arene oxides
nd nitrenium ions) react primarily with “soft” nucleophiles such
s the sulfhydryl group in cysteine. “Hard” electrophiles (such asorts 2 (2015) 1024–1032
aldehydes) react preferentially with “hard” nucleophiles such as
lysine, histidine and arginine. We  tested the qualitative trapping
properties of three synthetic d-peptides with different sequences
and compared their binding properties to that of GSH using mouse
and human liver microsomes as catalyzing enzyme source. Adduct
formation and fragment ion identiﬁcations were evaluated with
six structurally different compounds: amlodipine, caffeine, cloza-
pine, ibuprofen, nimesulide and ticlopidine (Table 1). The adducts
formed were analyzed by LC/MS ion-trap mass-spectrometry with
an ESI source. Species-dependent differences and similarities were
observed in the formation of adducts: the “safe” compounds
(amlodipine, caffeine, ibuprofen) resulted in divergent reading of
adducts while the “risky” agents (clozapine, nimesulide, ticlopi-
dine) produced adducts in both platforms and did not exhibit any
“species-dependent” or trapping agent speciﬁcity in adduct for-
mation. This consistent adduct reading for the “risky” compounds
suggests unequivocally that reactive metabolite(s) can bind to any
of the potentially reactive amino acid residues. However, different
peptides exhibited their own distinctive trapping characteristics
because of their different amino acid sequences, which are distinct
from that of the gold standard GSH, which has the ﬁxed sequence:
-glu–cys–gly and the nucleophilic thiol of the cysteine residue.
Bioanalytical techniques, including the detection of GSH adducts
and covalent binding assessment using radiolabeled chemical enti-
ties, have been used during lead optimization in the nonclinical
phase of drug development to identify and minimize reactive
metabolite formation [3,5,10]. The formation of reactive metabo-
lites and their covalent binding to macromolecules are thought to
be important — but not the only processes in the toxic reactions
evoked by drugs.
Amlodipine has been considered as a very safe drug for hyper-
tension [18]. It is one of the 1,4-dihydropyridine calcium channel
blockers and it does not contain any obvious structural alerts. In
this test, amlodipine did not produce any adducts with either GSH
or any of the peptides, irrespective of whether the activating sys-
tem was  based on human or mouse liver microsomes. However,
this drug is known to be metabolized to at least 21 different sta-
ble metabolites in primary rat hepatocytes [47]. The lack of GSH or
peptide targeting adduct with a human enzyme source refers to the
lack of generation of reactive intermediates in our test platform.
Caffeine (1,3,7-trimethylxanthine) is generally recognized as
“safe” with moderate daily use, although it is subject to metabolism
through several pathways. Caffeine can be oxidized at four
positions: 3-N-demethylation to produce paraxanthine, 1-N-
demethylation to produce theobromine, 7-N-demethylation to
produce theophylline, and 8-hydroxylation to produce 1,3,7-
trimethyluric acid. 3-N-demethylation is the main oxidation
pathway of caffeine in human liver microsomes as compared to
1-N- and 7-N-demethylation and 3-N-demethylation [4]. Perhaps
because of the several functionalization reactions that can occur,
caffeine formed an adduct with Peptide1 in the incubation with
human liver microsomes that has not been previously described in
the literature. However, no adducts were found with GSH or peptide
2 and 3.
Ibuprofen is a well-tolerated nonsteroidal anti-inﬂammatory
drug (NSAID) causing only a low incidence of serious adverse reac-
tions [46]. It is metabolized to form an acyl glucuronide, as well
as carboxyibuprofen and hydroxyibuprofen, which are excreted in
the urine together with the parent drug Geisslinger, 1989. Ibupro-
fen has been shown to react catalytically with several proteins
including the UDP-glucuronosyltransferases, which catalyze these
conjugation reactions [41]. In our study, ibuprofen formed only one
adduct in incubations with both human and mouse liver micro-
somes (+ O + peptide) with Peptide 1 (Fig. 2; Table 1) and no other
adducts were formed with any other trapping agents. However,
these adducts had different retention times with mouse (13.8)
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Table  1
The trapping agents, the substrates, the formed adducts with their retention times and fragment ions. GSH and D-peptiDe adducts of test compounds. The substrates (50 M)
were  incubated with mouse or human liver microsomes at CYP oxidizing conditions in the presence of GSH or peptide and then analysed by LC/MS ion-trap mass-spectrometry
with  an electrospray ionization source. -, no adduct or fragment ion could be identiﬁed.
GSH adduct
Substrate Mouse, tR (min) Fragment ions Human, tR (min) Fragment ions
Clinically safe Amlodipine – – – –
Caffeine – – – –
Ibuprofen – – – –
Clinically risky Clozapine +GSH (14.3) 316.7(M + 2H, calc 316.6),
632.2 (MH, calc 632.2), 503.2
(y2, calc 503.2), 614.2
(M + H−H2O, calc 614.2), 359.2
(Drug + SH, calc 359.1)
+GSH (14.3) 316.6(M + 2H, calc
316.6), 632.3 (MH, calc
632.2), 503.1 (y2, calc
503.2), 614.1
(M + H−H2O, calc
614.2), 359.2
(Drug + SH,  calc 359.1)
316.6(M + 2H, calc 316.6),
503.2 (y2, calc 503.2), 359.2
(Drug + SH, calc 359.1)
316.6(M + 2H, calc
316.6), 503.2 (y2, calc
503.2), 359.2
(Drug + SH,  calc 359.1)
309.6 (M + 2H, calc 309.6),
618.1 (M + H, calc 618.2), 489.2
(y2, calc 489.1), 345.1
(Drug−CH2 + SH, calc 345.1)
–
+GSH (14.1) – +GSH (14.1)
324.7 (M + 2H, calc
324.6), 648.2 (M + H,
calc 648.2), 519.2 (y2,
calc 519.2), 630.1
(M−H2O, calc 630.2)
−CH2 + GSH (14.0) –
–  +O + GSH (14.5)
Nimesulide -NO2 + OH + GSH
(14.9)
585.0 (M + H, calc 585.1), 456.1
(y2, calc 456.1)
-NO2 + OH n+ GSH
(14.9)
585.0 (M + H, calc
585.1), 456.1 (y2, calc
456.1)
584.1 (M + H, calc 584.1), 455.1
(y2, calc 455.1)
584.1 (M + H, calc
584.1), 455.1 (y2, calc
455.1)
−2O  + 2H + GSH
(15.0)
−2O + 2H + GSH
(15.0)
Ticlopidine +GSH (14.3) 569.0 (M + H, calc 569.1), 440.1
(y2, calc 440.1), 551.2
(M + H−H2O, calc 551.1)
–
569.0 (M + H, calc 569.1), 440.0
(y2, calc 440.1), 551.2
(M + H−H2O, calc 551.1)
+GSH (14.7) –
294.2 (M + 2H, calc 294.1),
587.1 (M + H, calc 587.1), 458.1
(y2, calc 458.1), 569.2
(M + H−H2O, calc 569.1)
+2H+O+GSH (12.2) 294.2 (M + 2H, calc 294.1),
587.1 (M + H, calc 587.1), 458.1
(y2, calc 458.1), 569.2
(M + H−H2O, calc 569.1)
+2H+O+GSH (12.2) 294.2 (M + 2H, calc
294.1), 587.1 (M + H,
calc 587.1), 458.1 (y2,
calc 458.1), 569.1
(M + H−H2O, calc
569.1)
302.2 (M + 2H, calc 302.1),
603.1 (M + H, calc 603.1), 474.1
(y2, calc 474.1), 585.1
(M + H−H2O, calc 585.1)
294.2 (M + 2H, calc
294.1), 587.1 (M + H,
calc 587.1), 458.0 (y2,
calc 458.1), 569.1
(M + H−H2O, calc
569.1)
+2H  + O + GSH
(13.0)
571.0 (M + H, calc 571.1), 264.1
(Drug + H, calc 264.1), 308.1
(GSH + H, calc 308.1
+2H+O+GSH (13.0) 302.1 (M + 2H, calc
302.1), 603.1 (M + H,
calc 603.1), 474.1 (y2,
calc 474.1), 585.2
(M + H-H2O, calc 585.1)
301.1 (M + 2H, calc 301.1),
601.1 (M + H, calc 601.1), 472.1
(y2, calc 472.1), 583.0
(M + H−H2O, calc 583.0)
+2H + 2O + GSH
(13.3)
+2H + 2O + GSH
(13.3)
+2H + GSH (13.4) –
+2O + GSH (13.7) –
1028 J.E. Laine et al. / Toxicology Reports 2 (2015) 1024–1032
Table 1 (Continued )
Peptide 1 (gly–tyr–pro–cys–pro–his–pro) adduct
Clinically safe Substrate Mouse, tR (min) Fragment ions Human, tR (min) Fragment ions
Amlodipine – –
Caffeine – 742.3 (y5, calc 742.3),
371.7 (y5 +2, calc
371.7), 847.0 (b6, calc
847.3), 193.1 (a2, calc
193.1), 221.1 (b2, calc
221.1)
Ibuprofen +O + pep (13.8)* – 770.2 (y5, calc
770.4), 385.6 (y5
+2, calc 385.7),
875.8 (b6, calc
875.4)
– +O + pep (14.4) 495.6 (M + 2H, calc
495.7), 350.2 (y3, calc
350.2), 673.3 (y4,
673.3), 770.3 (y5, calc
770.4), 385.7 (y5 +2,
calc 385.7), 193.1 (a2,
calc 193.1), 221.0 (b2,
calc 221.0), 875.3 (b6,
calc 875.4)
Clinically risky Clozapine +pep (14.0) – 547.7 (M+2H, calc
547.7), 874.2 (y5,
calc 874.3), 437.8
(y5 +2, calc 437.7) ,
979.2 (b6, calc
979.4), 490.3 (b6
+2, calc 490.2),
359.1 (Drug + SH,
calc 359.1)
+pep (14.0) 547.7 (M + 2H, calc
547.7), 874.2 (y5, calc
874.3), 437.8 (y5 +2,
calc 437.7) , 979.2 (b6,
calc 979.4), 490.2 (b6
+2, calc 490.2), 359.2
(Drug + SH, calc 359.1)
Nimesulide -2O + 2H + pep
(15.0)*
826.2 (y5, calc
826.3), 413.8 (y5
+2, calc 413.7),
221.0 (b2, calc
221.1), 931.1 (b6,
calc 931.3)
−2O + 2H + pep
(15.0)*
826.2 (y5, calc 826.3),
413.6 (y5 +2, calc
413.7), 221.0 (b2, calc
221.1)
Ticlopidine – – +2H + O + pep (13.9) 525.2 (M + 2H, calc
525.2), 829.1 (y5, calc
829.3), 415.2 (y5 +2,
calc 415.2), 193.1 (a2,
calc 193.1), 221.0 (b2,
calc 221.0), 934.1 (b6,
calc 934.3), 467.7 (b6
+2, calc 467.7)
–  – +2H + 2O + pep
(14.1)*
845.2 (y5, calc 845.3),
423.1 (y5 +2, calc
423.1), 193.1 (a2, calc
193.1)
–  – +2H + 2O + pep
(14.9)*
845.0 (y5, calc 845.3),
423.0 (y5 +2, calc
423.1), 193.1 (a2, calc
193.1), 221.1 (b2, calc
221.0), 950.0 (b6, calc
950.3), 296.1
(M + H−peptide calc
296.1), 770.2
(M + Hdrug, calc 770.3)
–  – +2H + pep (14.2) 517.1 (M + 2H, calc
517.2), 264.1
(M + Hpeptide,
calc 264.1), 770.2
(M + H−drug,
calc 770.3)
–  – +H−Cl + pep (14.5) 499.2 (M + 2H, calc
499.2), 648.1 (b4, calc
648.2), 745.1 (b5,
745.3), 882.1 (b6, calc
882.3), 441.7 (b6 +2,
calc 441.7)
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Table  1 (Continued )
Peptide 2 (gly–tyr–pro–ala–pro–his–pro) adduct
Substrate Mouse, tR (min) Fragment ions Human, tR (min) Fragment ions
Clinically safe Amlodipine – – – –
Caffeine – – – –
Ibuprofen – – – –
Clinically risky Clozapine – – – –
Nimesulide – – – –
Ticlopidine +pep(14.7) 500.2 (M + 2H, calc 500.2),
650.2 (b4, calc 650.2), 747.2
(b5, calc 747.3), 884.2 (b6, calc
884.3), 442.7 (b6 +2, calc
442.7), 428.6 (a6 +2, calc 428.7)
+pep(14.7)* 482.1 (b2, calc
482.1), 650.1 (b4,
calc 650.2), 747.2
(b5, calc 747.3),
884.3 (b6, calc
884.3), 442.7 (b6
+2, calc 442.7),
428.7 (a6 +2, calc
428.7)
500.2 (M + 2H, calc 500.2),
518.2 (y5, calc 518.3), 681.3
(y6, calc 681.3), 482.0 (b2, calc
482.1), 442.6 (b6 +2, calc
442.7), 262.0 (M+H-peptide,
calc 262.1), 738.2 (M + H−drug,
calc 738.4)
500.2 (M + 2H,  calc
500.2), 518.2 (y5,
calc 518.3) 482.1
(b2, calc 482.1),
262.1
(M + H-peptide,
calc 262.1), 738.4
(M + H−drug, calc
738.4)
516.1 (M + 2H, calc 516.2),
518.7 (y5, calc 518.3), 916.0
(b6, calc 916.3), 458.7 (b6 +2,
calc 458.7), 294.0
(M + H−peptide, calc 294.1),
738.2 (M + H−drug, calc 738.4)
+pep (15.7) +pep (15.7) 516.3 (M + 2H, calc
516.2), 916.1 (b6,
calc 916.3), 458.7
(b6 +2, calc 458.7),
294.0
(M + H-peptide,
calc 294.1), 738.2
(M + H−drug, calc
738.4)
484.2 (M + 2H, calc 484.2),
518.3 (y5, calc 518.3), 618.3
(b4, calc 618.3), 715.3 (b5, calc
715.3), 852.1 (b6, calc 852.4),
426.7 (b6 +2, 426.7), 412.6 (a6
+2, calc 412.7), 435.8 (b6 + H2O
+2, calc 435.7)
+2O + pep (15.7) +2O + pep (15.7)
−S−2H + pep (14.6) –
Peptide 3 (gly–tyr–arg–pro–cys–pro–his–lys–pro) adduct
Substrate Mouse, tR (min)
Fragment ions
Human, tR (min)
Fragment ions
Clinically safe Amlodipine – – – –
Caffeine – – – –
Ibuprofen – – – –
Clinically risky Clozapine +pep (12.6) 689.7 (M + 2H, calc
689.8), 1135.4 (b7,
calc 1135.5), 568.3
(b7 +2, calc 568.2),
632.5 (b8 +2, calc
632.3)
+pep (12.6) 689.9 (M + 2H, calc
689.8), 1135.3 (b7,
calc 1135.5), 568.2
(b7 +2, calc 568.2),
632.4 (b8 +2, calc
632.3)
Nimesulide – -NO2 + OH + pep
(12.8)
666.4 (M + 2H, calc
666.3), 1088.4 (b7,
calc 1088.4), 544.6
(b7 +2, calc 544.7),
1216.9 (b8, calc
1216.5), 608.8 (b8
+2, calc 608.8)
Ticlopidine – – – –
* Due to low signal, full scan mass spectrum could not be obtained.
Rationale behind the used abbreviations: +GSH/peptide, direct adduction with GSH/peptide; −CH2 + GSH/peptide, demethylation reaction before adduction with GSH;
+O  + GSH/peptide, introduction of O molecule and adduction with GSH/peptide; −NO2 + OH + GSH/peptide, elimination of NO2 group, introducing an OH group and adduction
with  GSH/peptide; −2O + 2H + GSH/peptide, two  oxygen molecules removed, two  H atoms added and adducted with GSH/peptide; +2O + GSH/peptide, two O molecules added
and  adducted with GSH/peptide; +2H + GSH/peptide, two  H molecules removed and adducted with GSH/peptide; +H + peptide, two H molecules added and adducted with
peptide.
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nd human (14.4) tissue. This may  be due to tissue-speciﬁc dif-
erences in metabolism, such that the trapping agent is binding
o different reactive sites on the ibuprofen molecule. Recently,
 report appeared about novel metabolites of ibuprofen, namely
buprofen-N-acyl-cysteinylglycine, ibuprofen-N-acyl-cysteine, and
he mercapturic acid conjugate, ibuprofen-S-acyl-N-acetylcysteine
11]. Based on the clinical safety proﬁle, the toxicological signiﬁ-
ance of the adduct is questionable, so that this may  be an example
f an adduction without toxicological signiﬁcance. Once again, the
ack of GSH, peptide 2 and 3 adducts with a human enzyme appears
o be a reﬂection of the good clinical safety proﬁle of the drug.
Clozapine is an antipsychotic drug with a well-known potential
o cause adverse reactions in its clinical use, such as myocarditis
r cardiomyopathy [12,50] and fatal neutropenia, agranulocytosis,
nd hepatotoxicity [1,30]. Clozapine is metabolized by cytochrome
450 (CYP) enzymes to form reactive metabolites such as a nitre-
ium ion, resulting in activated neutrophils and bone marrow cells
35]. In our tests, clozapine formed three adducts with GSH with
uman and mouse liver microsomes. Two clozapine + GSH adducts
ere identiﬁed; these compounds were slightly different with
etention times 14.3 and 14.1 min. This is possibly due to the differ-
nces in the binding site of clozapine on the GSH molecule. The third
dduct was different when incubated with the human and mouse
iocatalysts. With mouse microsomes, the adduct –CH2 + GSH was
ormed with a retention time of 14.0 min  and with human micro-
omes + O + GSH had a retention time of 14.5 min. Both of the
ysteine containing peptides, 1 and 3, detected one adduct (+pep-
ide) with both liver microsomes, but no adduct was detected with
eptide 2 missing the cysteine residue. In line with our data, ﬁve
lozapine-GSH conjugates have been detected [2,10,43,37,53,60].
dditionally, covalent adducts of clozapine with proteins have been
etected by Western blotting [55] and covalent protein modiﬁca-
ions with electrochemistry/LC/MS [27]. Clozapine has been shown
o modify rat liver proteins, forming covalent adducts with rat liver
ytosolic and membrane fractions and a protein adduct in the bone
arrow of rats [7]. In line with these data, it is proposed that
lozapine–peptide adducts could serve as a surrogate endpoint to
imic  protein adducting characteristics, in situations where the
idely used trapping agent GSH will be overwhelmed. These results
uggest that short peptides with a cysteine residue(s) could be
esigned to mimic  potential target proteins, and used as a tool to
dentify/detect adverse responses caused by reactive metabolites.
Nimesulide is an anti-inﬂammatory drug that has caused
epatotoxicity [48]. Its use is known to deplete GSH stores
nd to evoke mitochondrial energy supply uncoupling and
xidative stress. Previously, several human nimesulide urinary
etabolites were identiﬁed, including hydroxynimesulide, amino
es-nitronimesulide, amino hydroxynimesulide and N-acetylated
etabolites. Most of the metabolites are naturally stable and not
lectrophilic. Moreover, the idiosyncratic toxicity associated with
imesulide cannot be directly attributed to any of the known
etabolites. However, these metabolites exhibit structural fea-
ures that could enable them to be oxidatively bioactivated to
eactive electrophilic species that can form adducts with macro-
olecules and peptides and may  be capable of triggering a
oxic response. The amino des-nitronimesulide metabolite is a
ighly electrophilic di-iminiquinone and is capable of forming
dducts with N-acetylcysteine [24]. In the present study, nime-
ulide formed two adducts (−NO2 + OH + GSH and −2O + 2H + GSH)
ith GSH when incubated with both microsomes. With Peptide
, one adduct (−2O + 2H + peptide) was formed with both micro-
omes. Peptide 3 formed one adduct with human liver microsomes
−NO2 + OH + peptide). These data conﬁrm that nimesulide pos-
esses macromolecule-adducting characteristics. Once again, the
onsistent formation of GSH adducts with both species and pep-orts 2 (2015) 1024–1032
tide adducts to cysteine residue containing peptides support the
hazardous nature of nimesulide.
Ticlopidine is a drug used to inhibit the actions of throm-
bocytes. It can cause serious hematological disorders [15] and
liver toxicity Previteral and Pagani, 2010. The thiophene moi-
ety of ticlopidine is mainly oxidized by CYP2C19 in humans,
leading to the formation of electrophilic reactive metabolites,
including thiophene S-oxide and thiophene epoxide, which can
undergo covalent binding to cellular proteins including CYP2C19
[13]. In our study, ticlopidine formed seven adducts with GSH
(+GSH (2), +2H + O + GSH (2), +2H + 2O + GSH, +2H + GSH, +2O + GSH)
with mouse liver microsomes. Of these adducts, two  slightly dif-
ferent + GSH adducts (with retention times 14.3 and 14.7 min)
were identiﬁed and two similarly different adducts +2H + O + GSH
(with retention times 12.2 and 13.0 min). That is possibly due
to stereochemistry and differences in the binding site of ticlopi-
dine on the GSH molecule. Two GSH adducts (+2H + O + GSH and
+2H + 2O + GSH) were also found with human liver microsomes,
of which +2H + O + GSH had two forms (with retention times 14.3
and 14.7 min). With Peptide 1, ﬁve adducts were formed with
human liver microsomes (+2H + O + peptide (2), +2H + 2O + peptide,
+2H + peptide, +H −Cl + peptide), but none with mouse liver micro-
somes. With respect to the adducts formed after incubation with
human microsomes, two  different +2H + 2O + peptide adduct forms
were found with retention times 14.1 and 14.9 min. With Pep-
tide 2, four adducts were formed with mouse liver microsomes
(+peptide (2), +2O + peptide and –S −2H + peptide). The + peptide
adduct was  present in two  forms with retention times 14.7 and
15.7 min. With human liver microsomes, three adducts (+peptide
(2) and 2O + peptide) were identiﬁed, and similarly the + peptide
adduct existed in two different forms (retention times 14.7 and
15.7 min). According to the literature, ticlopidine has been shown to
form different types of adducts with GSH [37], (+GSH), (+O + GSH),
(+2H + O + GSH) and (+2H + 2O + GSH) [2,53]. Direct conjugation of
ticlopidine to GSH has also been reported by [26], i.e., the site of con-
jugation is on one side of the molecule, namely the thiophene ring.
It should be noted that the presence of the thiophene moiety has
been associated with a signiﬁcant incidence of adverse reactions
in other drugs [28]. The wider number of ticlopidine-GSH adducts
and the adduction with two  d-peptides reveal the overall reactivity
of this compound.
Based on the above data from six different compounds, it is pos-
sible to use short synthetic peptides for hazard identiﬁcation and
to develop them further to identify reactive metabolites. In some
cases, this can give additional information of reactive metabolite
formation compared to GSH. For instance, could a peptide adduct
proﬁle predict hapten-based immunological reactivity? Based on
our data, GSH adduction as such, should still be considered as the
gold standard for predicting the bioreactivity of the compound
and reactivity/toxicity is proportional to the diversity of different
adducts detected. With “safe” compounds, no GSH adducts and only
a few peptide adducts were found: with amlodipine no adducts
were detected with either GSH or peptides. Caffeine formed one
peptide adduct with Peptide 1 that contains a cysteine residue
in the middle of the amino acid chain when human liver micro-
somes were used as a biocatalyst. Ibuprofen resulted in one Peptide
1 adduct with both microsomes. With the “risky” agents (clozap-
ine, nimesulide and ticlopidine) the list of adducts identiﬁed was
largely peptide-dependent; several adducts were formed with GSH
as well as with the peptides. Species differences were observed in
formation of adducts between human and mouse with the trapping
peptides and GSH. This is obviously due to species-dependent dif-
ferences in the metabolic characteristics of metabolizing enzymes
[34].
Our d-peptide — based trapping method allows straightforward
detection of the reactive metabolites by LC/MS based on fragment
J.E. Laine et al. / Toxicology Reports 2 (2015) 1024–1032 1031
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on analysis. It is well known that d-peptides are resistant to cer-
ain proteases [6,32], which can increase their half-life in analytes
39,21]. In our case, the beneﬁts are that the d-isomer peptides are
ot hydrolyzed during the incubations with microsomes, incuba-
ion times can be increased, and the relative amount of the formed
dducts can be more reliably compared to each other. Our results
lso indicate convincingly that the sequence of peptide – existence
f nucleophilic thiol of cysteine residue – affects adduction, which
ay  be used to classify differently reacting active metabolites.
. Conclusions
Detection of reactive metabolites is based on their conjuga-
ion with trapping agents simultaneously during their formation.
n vitro conditions were established to test adduct formation of
xidized xenobiotics between three d-peptide isomers and GSH.
ualitative adduct formation was tested with six structurally
ifferent compounds: amlodipine, caffeine, clozapine, ibuprofen,
imesulide and ticlopidine. The adducts formed were isolated
nd identiﬁed based on their fragment ions in LC/MS. Clozapine,
imesulide and ticlopidine produced adducts with both enzymatic
iocatalyst and trapping platforms (GSH or d-peptide), conﬁrm-
ng the generation of reactive intermediates with toxic potential.
he number of adducts was compound and d-peptide dependent.
ith “safe compounds”, no or at the most only a few adducts
ere formed and identiﬁed. Toxicological signiﬁcance of the above
entioned adducts remains to be evaluated further together with
ther safety variables. The peptide trapping method can be further
eveloped for the screening of reactive metabolites; the peptides
an be designed so that they can represent the proteins likely to
ndergo adduct formation in the human body. From the clinical
oint of view, whether peptide-targeting adduction contributes to
[(gly–tyr–pro–cys–pro–his–pro) adduct.
the idiosyncratic, allergic or other immunologically related adverse
reactions as demonstrated by the “risky” compounds, remain to be
resolved.
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